地诺单抗治疗骨转移疗效怎样？

Xgeva is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits osteoclast activation and development, reduces bone resorption, and increases bone density. Denosumab is indicated for the prevention of bone-related events in patients with bone metastases from solid tumors. Bone metastasis is a disease in which certain malignant tumors that originate outside bone tissue metastasize to bone tissue through blood. The main manifestations are bone damage and pain. Breast cancer is the cancer most likely to metastasize to bone.

Let’s take a look at the efficacy of denosumab in treating bone metastasis?

The approval of denosumab for the treatment of bone metastases was based on the results of three trials. These three randomized, double-blind trials included a total of 5723 tumor patients: Trial 1 was breast cancer patients with bone metastases; Trial 2 was prostate cancer patients with bone metastases; Trial 3 was solid tumors other than breast cancer and prostate cancer with bone metastases and multiple myeloma. The efficacy of denosumab and zoledronic acid (a bisphosphonate) was compared in the treatment of bone metastases in breast cancer, prostate cancer and other solid tumors, as well as in multiple myeloma.

Comprehensive analysis of these three studies showed that compared with zoledronic acid: denosumab prolonged the time to the patient's first adverse bone event (ARE) by 17%, or significantly delayed the median time to the first SRE by 8.2 months (27.6 months vs. 19.4 months for zoledronic acid); denosumab prolonged the time from the first to the recurrence of SRE in the study by 18%. Denosumab also significantly prolonged the time to worsening pain compared with zoledronic acid in patients with mild or no pain at study entry. Based on this, denosumab is also recommended in NCCN guidelines for patients with bone metastases from solid tumors.

It can be seen that it can effectively delay the progression of the disease and improve the quality of life of patients, which is a good choice for patients with bone metastasis.